Biogen Idec (NASDAQ:BIIB)

Biotechnology word cloud

Short Sellers Become More Focused in Major Biotechs

The short interest data are out for the August 14 settlement date. Biotech companies are considered a riskier group of stocks, with big upside and big downside. FDA rulings can ...
Read Full Story »
Sad lonely pensive old senior woman

Applied Genetic Solidifies Deal With Biogen

Applied Genetic Technologies Corp. (NASDAQ: AGTC) announced that the Biogen Inc. (NASDAQ: BIIB) equity investment as part of their collaboration has closed. As per the agreement that was set in ...
Read Full Story »
Biotechnology word cloud

Short Sellers Run for Cover From Major Biotechs

The short interest data are out for the July 31 settlement date. Biotech companies are considered a riskier group of stocks, with big upside and big downside. FDA rulings can ...
Read Full Story »
biotech

5 Top BioPharma Stocks That May Have Sold Off Too Much and Become Bargains

With many investors starting to get more scared about China, scared about Europe and even scared about the coming interest rate hike cycle from the Federal Reserve, some smart money ...
Read Full Story »
investor research

Top Analyst Upgrades and Downgrades: Adobe, Biogen, Google, PDC Energy, Rackspace, XL Group and Many More

Stocks were indicated lower after China weakened the value of its yuan to make exports more attractive. While this makes it harder for U.S. companies to export to China, it ...
Read Full Story »
biotech

3 Large Biotech Stocks to Buy Despite Higher Interest Rates Coming

With many now expecting interest rates to finally start the move higher as early as next month, it is a fascinating study to see how interest rates affect biotech stocks. ...
Read Full Story »
Comfortable hospital bed

Will Biogen Win From Novartis MS Drug Safety Label Change?

There are times when a negative piece of news in the BioPharma sector can actually help rival companies. Biogen Inc. (NASDAQ: BIIB) is a stock that has been battered of ...
Read Full Story »
Biotechnology word cloud

3 Potential Huge Takeover Targets in Biotech

Usually when you think of a biotech takeover, it is a large cap biotech or pharmaceutical company that dives in and buys a small market cap stock with solid clinical ...
Read Full Story »
78773961

Tech and Biotech See Big-Time Insider Buying This Week – Apple, Biogen, Qualcomm and More

Nothing like earnings season coming around to buy stock if you are an insider and your company happens to disappoint. While most of the S&P 500 companies have reported as ...
Read Full Story »
Bull and Bear

Top Analyst Upgrades and Downgrades: AT&T, Chesapeake, Facebook, Qualcomm, Weatherford and Many More

Stocks were indicated lower by almost 1% on Monday after China's Shanghai market suffered its biggest loss in about 8 years on Monday. The one trend that has held up ...
Read Full Story »
biotech

Short Sellers Back Off Major Biotechs

The short interest data are out for the July 15 settlement date. Biotech companies are considered a riskier group of stocks, with big upside and big downside. FDA rulings can ...
Read Full Story »
biotech

BioPharma Earnings Bracing for Merck, Pfizer, Amgen, Gilead

Pharmaceutical and Biotech investors are about to get a real show for earnings this week. Big Pharma will bring earnings from Dow Jones Industrial Average companies Merck & Co. Inc. ...
Read Full Story »
biotech

Why Biogen Shares Are Tumbling After Earnings Report

Biogen Inc. (NASDAQ: BIIB) reported second-quarter 2015 results before markets opened Friday. The biotech firm posted adjusted diluted earnings per share (EPS) of $4.22 on revenues of $2.59 billion. In ...
Read Full Story »
Money, US, $100 bills

What to Look for in Biogen Earnings Report

Biogen Inc. (NASDAQ: BIIB) is scheduled to release its second-quarter financial results before the markets open on Friday. Thomson Reuters has consensus estimates of $4.10 in earnings per share (EPS) ...
Read Full Story »
152498601

Biogen Faces Mixed Alzheimer’s Reception

Biogen Inc. (NASDAQ: BIIB) may have dropped Idec from its name recently, but now the company appears to be dropping some of the bullish hopes for its Alzheimer's drug candidate. ...
Read Full Story »